NEW YORK, NY / ACCESSWIRE / October 20, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Blink Charging Company (NASDAQ: BLNK)
Class Period: March 6, 2020 - August 19, 2020
Lead Plaintiff Deadline: October 23, 2020
During the class period, Blink Charging Company allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) many of Blink’s charging stations are damaged, neglected, non-functional, inaccessible, nor non-accessible; (ii) Blink’s purported partnerships and expansions with other companies were overstated; (iii) the purported growth of the Company’s network has been overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in BLNK: http://www.kleinstocklaw.com/pslra-1/blink-charging-company-loss-submission-form?id=10294&from=1
Anaplan Inc. (NYSE: PLAN)
Class Period: November 21, 2019 - February 26, 2020
Lead Plaintiff Deadline: October 23, 2020
The complaint alleges Anaplan Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was undergoing sales organization and execution challenges; (2) these organizational challenges were causing the Company to miss on closing very important large deals; and (3) as a result, Anaplan’s financial guidance for “calculated billings growth” was baseless and unattainable. Further, while in possession of this material non-public information, Anaplan insiders dumped approximately $30 million worth of Anaplan stock at artificially inflated prices.
Learn about your recoverable losses in PLAN: http://www.kleinstocklaw.com/pslra-1/anaplan-inc-loss-submission-form?id=10294&from=1
Nextcure, Inc. (NASDAQ: NXTC)
The Nextcure lawsuit was filed on behalf of investors who purchased Nextcure, Inc. (NASDAQ: NXTC) securities: (1) between November 5, 2019 and July 14, 2020, inclusive; and/or (2) pursuant or traceable to the company's secondary public offering declared effective on November 14, 2019.
Lead Plaintiff Deadline: November 20, 2020
Throughout the class period defendants’ statements were materially misleading because the data Defendants possessed on its principle product candidate, NC318, showed a lack of efficacy and objective responses. Had the truth been revealed, the market would have seen that NC318 was not, in fact, effective in treating most tumor types, that the NC318 application was proving to be limited (if even useful at all), and, as a result, there was a significant realizable risk that NC318 would not be nearly as popular as then-existing blockbuster drugs, such as Keytruda.
Learn about your recoverable losses in NXTC: http://www.kleinstocklaw.com/pslra-1/nextcure-inc-loss-submission-form?id=10294&from=1
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm